Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
Condition(s):Thrombotic Microangiopathies; Atypical Hemolytic Uremic SyndromeLast Updated:October 18, 2018Unknown status
Hide Studies Not Open or Pending
Condition(s):Thrombotic Microangiopathies; Atypical Hemolytic Uremic SyndromeLast Updated:October 18, 2018Unknown status
Condition(s):IgAN; Lupus Nephritis; MN; C3 GlomerulopathyLast Updated:April 10, 2020Unknown status
Condition(s):Systemic SclerosisLast Updated:March 21, 2022Completed
Condition(s):COVID-19, SARS-CoV-2Last Updated:February 12, 2024Active, not recruiting
Condition(s):Healthy Adult Immune ResponseLast Updated:December 30, 2020Terminated
Condition(s):Growth Hormone DeficiencyLast Updated:March 9, 2018Terminated
Condition(s):Ovarian NeoplasmsLast Updated:January 10, 2013Completed
Condition(s):Rheumatoid ArthritisLast Updated:March 28, 2022Completed
Condition(s):HIVLast Updated:January 11, 2024Completed
Condition(s):Solid TumorsLast Updated:March 6, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.